Early Immune-State Indicators as Predictors of Failure and Success in Combination Immunotherapy

Combination immunotherapies for solid tumors increasingly rely on multi-component regimens designed to activate complementary immune pathways. Despite strong mechanistic rationale, durable clinical benefit remains limited for many patients, and treatment failure is often recognized only after prolonged exposure and cumulative toxicity. This paper proposes that immune commitment to success or failure occurs early in treatment and is reflected in structured, interpretable immune state indicators that emerge weeks before conventional efficacy endpoints. We develop a conceptual and operational framework in which early immune responses are understood as conditional state transitions rather than linear accumulations of activity. By organizing early immune indicators into functional categories—effector dynamics and persistence, antigen engagement, inflammatory balance, and tumor microenvironment responsiveness—we show how these patterns map onto underlying conditional dependencies required for durable anti-tumor immunity. Failure to satisfy key dependencies in the appropriate sequence produces recurrent, predictable failure trajectories, even when individual therapeutic components are biologically active. Linking early immune indicators to dependency logic provides a mechanistically grounded basis for early prediction of patient-specific outcomes. This framework supports adaptive clinical decision-making, including early identification of likely non-responders, rational resequencing of therapeutic components, and avoidance of prolonged exposure to ineffective regimens. We further examine implications for trial design, emphasizing early immune state endpoints, adaptive trial structures, and reinterpretation of negative or equivocal combination immunotherapy results. Recognizing immune commitment as an early, constrained process reframes how combination immunotherapies are evaluated and applied. Integrating early immune state assessment into clinical and research workflows has the potential to improve patient outcomes, reduce unnecessary harm, and accelerate learning in combination immunotherapy development, while preserving ethical safeguards and scientific rigor. Keywords: combination immunotherapy; immune commitment; early immune indicators; conditional dependency; systems immunology; adaptive trial design; tumor microenvironment; translational oncology